Jose M. Ferro (Portugal)

Hospital de Santa Maria, CHULN; Universidade de Lisboa Department of Neurosciences (Neurology)
José M. Ferro was born in Lisbon, Portugal, on the 22nd October 1951. He graduated in 1975 and received his PhD in Medicine in 1987 from the the University of Lisbon. He was a post-doctoral fellow at the Department of Clinical Neurological Sciences, London, Canada. He is currently Full Professor of Neurology at the Faculdade de Medicina, Universidade de Lisboa, and Director of the Department of Neurosciences and Mental Health and of the Neurology Service at the Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, EPE. He is Principal Investigator at the Instituto de Medicina Molecular João Lobo Antunes, University of Lisbon. He was President of the European Neurological Society, Chairman of the Stroke Portuguese Society and member of the Scientific Panel for Health of the Directorate-General for Research and Innovation, Directorate E – Health of the European Commission. Has authored or co-authored 360 papers published in peer-reviewed journals and 60 book chapters. His research interest focuses on cerebrovascular disease, in particular cerebral venous thrombosis, cryptogenic stroke, stroke in systemic diseases and neuropsychiatric consequences of stroke.

Author Of 2 Presentations

Post-stroke Depression, Apathy and Anxiety

Session Type
Main Theme Symposium
Date
29.10.2021, Friday
Session Time
08:00 - 09:30
Room
MAIN THEME A
Lecture Time
08:20 - 08:40

Abstract

Abstract Body

The aim of this lecture is to update the audience on the most common neuropsychiatric disorders after stroke, namely poststroke depression, apathy and anxiety, which affect more than 1/3 of stroke survivors. We will detail the epidemiological and clinical features of these disturbances, and describe available screening instruments and DSM V diagnostic criteria. Recent advances on pathophysiology will be discussed, based on neuroimaging mapping of stroke lesions and functional MR studies. Recent evidence on the management of depression, apathy and anxiety will be reviewed. Depression, apathy and anxiety may persist despite best available management and may relapse. These neuropsychiatric disturbance have a negative impact on the rehabilitation and Quality of Life of persons who survived an acute stroke

Hide

POST-SARS-COV-2-VACCINATION CEREBRAL VENOUS SINUS THROMBOSIS: AN ANALYSIS OF CASES NOTIFIED TO THE EUROPEAN MEDICINES AGENCY

Session Type
Free Communication Session
Date
28.10.2021, Thursday
Session Time
15:45 - 17:15
Room
FREE COMMUNICATIONS A
Lecture Time
15:45 - 15:55

Abstract

Background and Aims

Cerebral venous sinus thrombosis (CVST) has been described after vaccination against SARS-CoV-2. We report clinical characteristics of 213 post-vaccination CVST cases notified to the European Medicines Agency (EMA).

Methods

Data on Adverse Drug Reactions (ADRs) after SARS-CoV-2 vaccination notified until 8 April 2021 under the Medical Dictionary for Regulatory Activities Term ‘Central nervous system vascular disorders’ were obtained from the EudraVigilance database. We compared post-vaccination CVST to 100 European patients with CVST from before the COVID-19 pandemic (2015-2018) derived from the International CVST Consortium.

Results

We identified 213 CVST cases: 187 after ChAdOx1 nCov-19 vaccination and 26 after a mRNA vaccine (25 BNT162b2 and 1 mRNA-1273).. Thrombocytopenia was reported in 107 CVST cases (57%, 95%CI 50-64%) in the ChAdOx1 nCov-19 group, in none in the mRNA vaccine group (0%, 95%CI 0-13%), and in 7 (7%, 95%CI 3-14%) in the pre-COVID-19 group. In the ChAdOx1 nCov-19 group, there were 39 (21%) reported COVID-19 PCR tests performed within 30 days of CVST symptom onset, all were negative. Of the 117 patients with a reported outcome in the ChAdOx1 nCov-19 group, 44 (38%, 95%CI 29-47%) had died, compared to 2/10 (20%, 95%CI 6-51%) in the mRNA vaccine group and 3/100 (3%, 95%CI 1-8%) in the pre-COVID-19 group. Mortality among patients with thrombocytopenia in the ChAdOx1 nCov-19 group was 49% (95%CI 39-60%).

Conclusions

Analysis of EMA data shows that CVST occurring after ChAdOx1 nCov-19 vaccination has a clinical profile distinct from CVST unrelated to vaccination. Thrombocytopenia was associated only with CVST after ChAdOx1 nCov-19 vaccination.

Hide

Presenter of 1 Presentation

Post-stroke Depression, Apathy and Anxiety

Session Type
Main Theme Symposium
Date
29.10.2021, Friday
Session Time
08:00 - 09:30
Room
MAIN THEME A
Lecture Time
08:20 - 08:40

Abstract

Abstract Body

The aim of this lecture is to update the audience on the most common neuropsychiatric disorders after stroke, namely poststroke depression, apathy and anxiety, which affect more than 1/3 of stroke survivors. We will detail the epidemiological and clinical features of these disturbances, and describe available screening instruments and DSM V diagnostic criteria. Recent advances on pathophysiology will be discussed, based on neuroimaging mapping of stroke lesions and functional MR studies. Recent evidence on the management of depression, apathy and anxiety will be reviewed. Depression, apathy and anxiety may persist despite best available management and may relapse. These neuropsychiatric disturbance have a negative impact on the rehabilitation and Quality of Life of persons who survived an acute stroke

Hide